Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD

NCT02642614 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: BI 1026706
DRUG: Placebo
DRUG: Placebo

Sponsor

Boehringer Ingelheim